Inhibikase Therapeutics (IKT) Accumulated Depreciation & Amortization (2022 - 2025)
Inhibikase Therapeutics (IKT) has disclosed Accumulated Depreciation & Amortization for 4 consecutive years, with $117224.0 as the latest value for Q3 2025.
- On a quarterly basis, Accumulated Depreciation & Amortization rose 133.71% to $117224.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $117224.0, a 133.71% increase, with the full-year FY2024 number at $56725.0, up 86.27% from a year prior.
- Accumulated Depreciation & Amortization was $117224.0 for Q3 2025 at Inhibikase Therapeutics, up from $93537.0 in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $170970.0 in Q2 2023 to a low of $1681.0 in Q3 2022.
- A 4-year average of $54854.8 and a median of $43590.0 in 2024 define the central range for Accumulated Depreciation & Amortization.
- Peak YoY movement for Accumulated Depreciation & Amortization: soared 1320.88% in 2023, then crashed 74.5% in 2024.
- Inhibikase Therapeutics' Accumulated Depreciation & Amortization stood at $6723.0 in 2022, then surged by 352.97% to $30453.0 in 2023, then skyrocketed by 86.27% to $56725.0 in 2024, then skyrocketed by 106.65% to $117224.0 in 2025.
- Per Business Quant, the three most recent readings for IKT's Accumulated Depreciation & Amortization are $117224.0 (Q3 2025), $93537.0 (Q2 2025), and $69379.0 (Q1 2025).